On this page
Desoximetasone
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 076510-001 | DESOXIMETASONE | CREAM | DESOXIMETASONE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | July 1, 2003 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260511). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply a thin film of desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, or desoximetasone gel USP, 0.05% to the affected skin areas twice daily. Rub in gently.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Warnings and Cautions
openFDA Drug LabelingWARNINGS Keep out of reach of children.
Warnings
openFDA Drug LabelingWARNINGS Desoximetasone Cream USP, 0.25% is not for ophthalmic use. Keep out of reach of children.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies the incidence of adverse reactions were low (0.8%) for desoximetasone cream USP, 0.25%, and included burning, folliculitis, and folliculo-pustular lesions. The incidence of adverse reactions were also 0.8% for desoximetasone cream USP, 0.05% and included pruritus, erythema, vesiculation, and burning sensation. The incidence of adverse reactions for desoximetasone gel USP, 0.05% was 0.3% with one subject reporting stinging and burning at the site of application.
Description
openFDA Drug LabelingDESCRIPTION Desoximetasone cream USP, 0.05%, desoximetasone cream USP, 0.25%, and desoximetasone gel USP, 0.05% contain the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Each gram of desoximetasone cream USP, 0.05% contains 0.5 mg of desoximetasone in an emollient cream base consisting of cetostearyl alcohol, edetate disodium, isopropyl myristate, lanolin alcohol, mineral oil, purified water, and white petrolatum. Each gram of desoximetasone cream USP, 0.25% contains 2.5 mg of desoximetasone in an emollient cream base consisting of cetostearyl alcohol, isopropyl myristate, lanolin alcohol, mineral oil, purified water, and white petrolatum. Each gram of desoximetasone gel USP, 0.05% contains 0.5 mg of desoximetasone in a gel base consisting of carbomer 940, docusate sodium, edetate disodium, isopropyl myristate, purified water, SDAG-3 95% alcohol, and trolamine. The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11ß,16α)-. Desoximetasone has the molecular formula C 22 H 29 FO 4 and a molecular weight of 376.47. The CAS Registry Number is 382-67-2. The structural formula is: Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects ( see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Desoximetasone cream USP, 0.05% is supplied in: 15 gram (NDC 51672-1271-1), 30 gram (NDC 51672-1271-2), 60 gram (NDC 51672-1271-3), and 100 gram (NDC 51672-1271-7) tubes. Desoximetasone cream USP, 0.25% is supplied in: 15 gram (NDC 51672-1270-1), 30 gram (NDC 51672-1270-2), 60 gram (NDC 51672-1270-3), and 100 gram (NDC 51672-1270-7) tubes. Desoximetasone gel USP, 0.05% is supplied in: 15 gram (NDC 51672-1261-1), 30 gram (NDC 51672-1261-2) and 60 gram (NDC 51672-1261-3) tubes. Store at controlled room temperature between 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: DESOXIMETASONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0597-0 | 50090-0597 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-0597-0) / 15 g in 1 TUBE | November 28, 2014 |
| 50090-5571-0 | 50090-5571 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-5571-0) / 15 g in 1 TUBE | June 25, 2021 |
| 72162-2330-2 | 72162-2330 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2330-2) / 15 g in 1 TUBE | June 18, 2024 |
| 68180-949-02 | 68180-949 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-949-02) / 60 g in 1 TUBE | June 20, 2017 |
| 68180-949-04 | 68180-949 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-949-04) / 100 g in 1 TUBE | June 20, 2017 |
| 68180-950-01 | 68180-950 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-950-01) / 15 g in 1 TUBE | June 20, 2017 |
| 68180-950-02 | 68180-950 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-950-02) / 60 g in 1 TUBE | June 20, 2017 |
| 68180-950-04 | 68180-950 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-950-04) / 100 g in 1 TUBE | June 20, 2017 |
| 45802-495-35 | 45802-495 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-495-35) / 15 g in 1 TUBE | November 16, 2006 |
| 45802-495-37 | 45802-495 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-495-37) / 60 g in 1 TUBE | October 24, 2006 |
| 63187-646-15 | 63187-646 | Proficient Rx LP | 1 TUBE in 1 CARTON (63187-646-15) / 15 g in 1 TUBE | December 1, 2018 |
| 63187-646-60 | 63187-646 | Proficient Rx LP | 1 TUBE in 1 CARTON (63187-646-60) / 60 g in 1 TUBE | December 1, 2018 |
| 71205-271-15 | 71205-271 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-271-15) / 15 g in 1 TUBE | May 1, 2019 |
| 71656-086-15 | 71656-086 | Saptalis Pharmaceuticals, LLC. | 15 TUBE in 1 CARTON (71656-086-15) / 15 g in 1 TUBE | April 13, 2026 |
| 71656-086-60 | 71656-086 | Saptalis Pharmaceuticals, LLC. | 60 TUBE in 1 CARTON (71656-086-60) / 60 g in 1 TUBE | April 13, 2026 |
| 71656-087-15 | 71656-087 | Saptalis Pharmaceuticals, LLC. | 15 TUBE in 1 CARTON (71656-087-15) / 15 g in 1 TUBE | May 7, 2026 |
| 71656-087-60 | 71656-087 | Saptalis Pharmaceuticals, LLC. | 60 TUBE in 1 CARTON (71656-087-60) / 60 g in 1 TUBE | May 7, 2026 |
| 51672-1270-1 | 51672-1270 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1270-1) / 15 g in 1 TUBE | November 30, 1990 |
| 51672-1270-2 | 51672-1270 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1270-2) / 30 g in 1 TUBE | November 30, 1990 |
| 51672-1270-3 | 51672-1270 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1270-3) / 60 g in 1 TUBE | November 30, 1990 |
| 51672-1270-7 | 51672-1270 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1270-7) / 100 g in 1 TUBE | November 30, 1990 |
| 51672-1271-1 | 51672-1271 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1271-1) / 15 g in 1 TUBE | November 30, 1990 |
| 51672-1271-2 | 51672-1271 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1271-2) / 30 g in 1 TUBE | November 30, 1990 |
| 51672-1271-3 | 51672-1271 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1271-3) / 60 g in 1 TUBE | November 30, 1990 |
| 51672-1271-7 | 51672-1271 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1271-7) / 100 g in 1 TUBE | November 30, 1990 |
| 72578-091-01 | 72578-091 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-091-01) / 15 g in 1 TUBE | August 31, 2020 |
| 72578-091-02 | 72578-091 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-091-02) / 60 g in 1 TUBE | August 31, 2020 |
| 72578-091-03 | 72578-091 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-091-03) / 100 g in 1 TUBE | August 31, 2020 |
| 70771-1437-0 | 70771-1437 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1437-0) / 100 g in 1 TUBE | February 12, 2019 |
| 70771-1437-1 | 70771-1437 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1437-1) / 15 g in 1 TUBE | February 12, 2019 |
| 70771-1437-3 | 70771-1437 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1437-3) / 60 g in 1 TUBE | February 12, 2019 |
| 50090-0597 | 50090-0597 | A-S Medication Solutions | — | October 24, 2006 |
| 50090-5571 | 50090-5571 | A-S Medication Solutions | — | November 30, 1990 |
| 72162-2330 | 72162-2330 | Bryant Ranch Prepack | — | October 24, 2006 |
| 68180-949 | 68180-949 | Lupin Pharmaceuticals, Inc. | — | June 20, 2017 |
| 68180-950 | 68180-950 | Lupin Pharmaceuticals, Inc. | — | June 20, 2017 |
| 45802-495 | 45802-495 | Padagis Israel Pharmaceuticals Ltd | — | October 24, 2006 |
| 63187-646 | 63187-646 | Proficient Rx LP | — | October 24, 2006 |
| 71205-271 | 71205-271 | Proficient Rx LP | — | March 31, 2016 |
| 71656-086 | 71656-086 | Saptalis Pharmaceuticals, LLC. | — | April 13, 2026 |
| 71656-087 | 71656-087 | Saptalis Pharmaceuticals, LLC. | — | May 7, 2026 |
| 51672-1270 | 51672-1270 | Sun Pharmaceutical Industries, Inc. | — | November 30, 1990 |
| 51672-1271 | 51672-1271 | Sun Pharmaceutical Industries, Inc. | — | November 30, 1990 |
| 72578-091 | 72578-091 | Viona Pharmaceuticals Inc | — | August 31, 2020 |
| 70771-1437 | 70771-1437 | Zydus Lifesciences Limited | — | February 12, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.